`
`
`Andrew S. Janoff
`25 Spring Street
`Number 310
`Princeton, NJ 08542
`
`Harvard Medical School, Research Fellow in Pharmacology
`Massachusetts General Hospital, Research Fellow in Anesthesia
`Michigan State University, Ph.D., Biophysics
`Michigan State University, M.S., Biophysics
`The American University, B.S., Biology
`
`
`
`
`
`
`EDUCATION
`
`1980 - 81
`1980 - 81
`1980
`1977
`1971
`
`
`PROFESSIONAL POSITIONS
`
`2014 Chairman, CEO, and President, Taaneh, Inc.
`
`2012- Expert Consultant
`
`2009-2011 CEO
` TranslationUP
`
`2005-2008
`
`
`1999-2007
`
`
`1996-2006
`
`
`
`2002 – 2005
`
`
`
`2001 - 2002
`
`
`
`1997 - 2001
`
`
`1997 - 1999
`
`
`1996 - 1997
`
`
`1993 - 1997
`
`
`
`
`Chairman and CEO
`Celator Pharmaceuticals, Inc., Princeton, New Jersey
`
`Visiting Research Collaborator, Department of Chemical Engineering
`Princeton University, Princeton, New Jersey
`
`Adjunct Professor, Department of Pathology, Anatomy & Cell Biology
`Thomas Jefferson University, Philadelphia, Pennsylvania
`
`Chairman and CEO
`Celator Technologies, Inc., Vancouver, British Columbia, Canada
`
`Chairman
`Celator Technologies, Inc., Vancouver, British Columbia, Canada
`
`Vice President of Research & Development
`The Liposome Company, Inc., Princeton, New Jersey
`
`Visiting Research Collaborator, Department of Molecular Biology
`Princeton University, Princeton, New Jersey
`
`Visiting Research Scholar, Department of Physics
`Princeton University, Princeton, New Jersey
`
`Vice President of Research
`The Liposome Company, Inc., Princeton, New Jersey
`
`Moderna Ex 1018-p. 1
`Moderna v Arbutus
`
`

`

`Adjunct Associate Professor of Pathology, Anatomy & Cell Biology
`Thomas Jefferson University, Philadelphia, Pennsylvania
`
`Adjunct Assistant Professor of Physiology & Biophysics
`Rutgers Medical School, Piscataway, New Jersey
`
`Executive Director of Research
`The Liposome Company, Inc., Princeton, New Jersey
`
`1988 - 1995
`
`
`
`1988 - 1993
`
`
`
`Director of Membrane Research
`1984 - 1988
` The Liposome Company, Inc., Princeton, New Jersey
`
`
`1981-1984 Senior Scientist
` The Liposome Company, Inc., Princeton, New Jersey
`
`1982 - 1988
`
`
`
`1981
`
`
`
`EDITORIAL POSITIONS
`
`
`
`
`
`Adjunct Assistant Professor of Biology
`Boston College, Chestnut Hill, Massachusetts
`
`2008- Editor Emeritus, The Journal of Liposome Research, Informa, New York.
`1997-2008 Editor-in-Chief, The Journal of Liposome Research Informa., New York.
`1994-1997 Editorial Board, The Journal of Liposome Research, Marcel Dekker Inc., New York.
` Editor, Liposomes: Rational Design, Marcel Dekker Inc., New York, 1999.
`1998-1999
`
`
`ADVISORY COMMITTEES/CONSULTING
`
`National Institutes of Health Advisory Committee on Antiphospholipid Antibodies and Thrombosis, 1987, 1991
`Ad hoc member, National Institutes of Health, Hematology Study Section, 1992
`Scientific Advisory Board, Rider University, Lawrenceville, New Jersey, 1990 - 1994
`The Committee on Science and the Arts, Franklin Institute, Philadelphia, Pennsylvania 1994 – 1996
`NATO Advanced Study Institute, Cape Sounion, Greece, 1997
`United States Food and Drug Administration, United States Pharmacopeia, American Association of Pharmaceutical
`Scientists Joint Symposia: Assuring Quality and Performance of Sustained and Controlled Release Parentials,
` Washington, D.C. 2001
`National Cancer Institute Developmental Therapeutics Program Symposium :Preclinical Models for Defining
`Efficacy of Drug Combinations, The National Cancer Institute, Frederick, Maryland, 2003
`Centre for Drug Research and Development, Vancouver, Canada 2009
`AstraZeneca, 2012
`Zydus Pharmaceuticals, 2014-present
`Alnylam Pharmaceuticals, 2012
`Viking Pharmaceuticals, 2014
`
`EXPERT TESTIMONY
`
`United States Federal District Court
`
`REVIEW GRANTS AND MANUSCRIPTS FOR
`
`National Institutes of Health
`National Science Foundation
`Proceedings of the National Academy of Sciences
`Science
`Nature
`Biochimica et Biophysica Acta
`
`Moderna Ex 1018-p. 2
`Moderna v Arbutus
`
`

`

`Biochemistry
`Biochemical Pharmacology
`Biophysical Journal
`Clinical Chemistry
`Chemistry and Physics of Lipids
`CRC Press, Inc.
`Journal of Biological Chemistry
`Journal of Pharmaceutical Sciences
`Journal of Liposome Research
`Journal of Theoretical Biology
`
`
`INVITED LECTURES (selected)
`
`Gordon Research Conference on Lipid Metabolism, 1985
`Swathmore College, Department of Chemistry, 1987
`Gordon Research Conference on Liposomes and Other Organized Lipid Assemblies, 1987
`Walter Reed Army Institute for Research, 1988
`Sigma Xi, Princeton Chapter, Guest Lecture, 1988
`Bayer Centenary Symposium, Perspectives in Antiinfective Therapy, Washington, D.C., 1988
`Fourth Annual Princeton Liposome Conference, Princeton, New Jersey, 1989
`Thomas Jefferson University, Pathology Grand Rounds, 1990
`International Society on Thrombosis & Hemostasis, 26 Annual Meeting, Barcelona, Spain, 1990
`Liposomes in Drug Delivery, Twenty-One Years On, London, England, 1990
`Bristol-Myers Squibb Pharmaceutical Research Institute Symposia on Systemic Fungal Disease, Princeton, New
`Jersey, 1990
`International Society on Thrombosis and Hemostasis, 27 Annual Meeting, Amsterdam, The Netherlands, 1991
`Contrast Media Research Conference, Cambridge, England, 1991
`Biomedical Engineering Society Annual Meeting, Charlottesville, Virginia, 1991
`Eighteenth Annual Western Canada Biomembranes Conference, Whistler, British Columbia, Canada, 1992
`Thirty-fourth International Conference on the Biochemistry of Lipids, Noordwijkerhout, The Netherlands, 1993
`The Fifth Princeton Liposome Conference, Princeton, New Jersey, 1993
`Liposomes as Biomimetics Conference, Rome, Italy, 1993
`Liposomes in Drug Delivery, London, England, 1993
`New York University Medical Center, Rheumatology Grand Rounds, 1994
`Liposomes as Biomembrane Models: Principles, Applications and interactions with Metals Ions and Biological
`Molecules, Sevilla, Spain, 1994
`Liposome Research Days, Vancouver, Canada, 1994
`Liposomes in Biomedical Research, Berlin, Germany, 1994
`A Liposome Birthday Conference: 1965 Back to the Future 1995, Cambridge, England, 1995
`Satellite Symposium: British Society for Haematology Annual Scientific Meeting, Brighton, England, 1995
`The Annual Congress of the Association of Faculties of Pharmacy of Canada, Montréal, Canada, 1995
`35th Interscience Conference on Antimicrobial Agents and Chemotherapy, San Francisco, California, 1995
`The Sixth Princeton Liposome Conference, Princeton, New Jersey, 1995
`Reunión de Farmacia Hospitalaria, Madrid, Spain, 1996
`Societat Catalana de Farmàcia Clínica Sessió Científica, Barcelona, Spain, 1996
`Symposium on Systemic Fungal Infections, Prague, 1996
`Pre-Congress Symposium at The IHS 9th International Symposium on Infections in the Immunocompromised Host,
`Assisi, Italy, 1996
`The Fifth Liposome Research Days, Shizuoka, Japan, 1996
`Simpósio de Lançamento ABELCET®, Lisboa, Portugal, 1996
`Liposome Advances: Progress in Drug and Vaccine Delivery, London, England, 1996
`4th International Antifungal Drug Discovery & Development Summit, Princeton, New Jersey, 1999
`American Chemical Society National Meeting, Anaheim, California, 1999
`Liposome Advances: Progress in Drug and Vaccine Delivery, London, England, 1999
`Gordon Research Conference on Drug Carriers in Medicine & Biology, Ventura, California, 2000
`7th Liposome Research Days Conference, Napa Valley, California, 2000
`Brookdale University Hospital, Hematology – Oncology Conference, 2000
`
`Moderna Ex 1018-p. 3
`Moderna v Arbutus
`
`

`

`Brooklyn Hospital Center, Hematology – Oncology Lecture Series, 2000
`Mount Sinai Hospital, Hematology – Oncology Grand Rounds, 2000
`The 27th International Symposium of Bioactive Materials, Paris, France, 2000
`US – Swiss Forum on NanoBiosciences, Princeton University, Princeton, New Jersey, 2000
`Ventures West CEO Summit, Vancouver, Canada, 2003
`Canadian Consulate Trade Office’s Venture Capital Advisory Board meeting, San Francisco, California, 2003
`Sixth International Conference, Liposome Advances: Progress in Drug and Vaccine Delivery, School of Pharmacy,
`University of London, England, 2003
`Canada-US Venture Capital Conference, Quebec City, Canada, 2004
`Controlled Release Society, 32nd Annual Meeting, Miami, Florida, 2005
`Lipids, Liposomes & Biomembranes Conference, Vancouver, Canada, 2005
`The Cancer Institute of New Jersey, Grand Rounds, 2005.
`RSC/KAST Bilateral Symposium: Drug Delivery Systems, Vancouver, Canada, 2005
`Advances in Drug Delivery, School of Pharmacy, University of London, 2007
`Piper Jaffray 19th Annual Heathcare Conference, 2007
`Biotech 2007 Conference, Philadelphia. (Invited Panelist-Funding Early Stage Bioscience Companies- Do You
`Have What It Takes?”)
`Mid Atlantic Capital Alliance Conference, 2007
`C21 Bioparterning Conference, 2007
`CDRD (seminar series), Vancouver British Columbia, 2009
`ILS Liposome Advances, Annual Meeting, London, England, 2009
`ILS Liposome Advances, Annual Meeting, London England, 2011 (session chair)
`ILS Liposome Advances annual Meeting, London England, 2013 (session chair)
`1st International Congress: From Drug Discovery to Drug Delivery. Athens, Greece, 2014 (keynote speaker)
`ILS/LRD Joint International Conference, Progress in Liposome Drug and Vaccine Delivery, Athens, Greece 2017
`(invited speaker)
`
`
`GRANTS
`
`Core Director - NIH RFA 90-IA-10; NCDDG for Treatment of AIDS: Opportunistic Infections, $4,315,876 (1991-
`1994).
`
`
`MEMBERSHIPS
`
` American Association for the Advancement of Science
` Biophysical Society
` New York Academy of Sciences
` International Liposome Society
` American Association for Cancer Research
` American Society for Clinical Oncology
`
`
`INVESTIGATIONAL NEW DRUG APPLICATIONS
`
`TLC™-D99 (Doxorubicin HCL Liposome Injection)
`1987
`1988 ABLC (Amphotericin B Lipid Complex)
`1990
`TLC™-G65 (Gentamicin Liposome Injection)
`TLCTM-C53 (Liposomal Prostaglandin E1 Injection)
`1992
`1998
` ELL-12 (Liposomal Ether Lipid)
`2001 BRT-216 (Bromoacylated Paclitaxel)
`2004 CPX-1 (Liposomal Floxuridine Irinotecan Injection; CTA)
`2006 CPX-1 (Liposomal Floxuridine Irinotecan Injection; IND)
`2006 CPX-351 (Liposomal Cytarabine Daunorubicin Injection)
`
`
`
`
`Moderna Ex 1018-p. 4
`Moderna v Arbutus
`
`

`

`
`
`NEW DRUG APPLICATIONS
`
`1995 ABELCET® (Amphotericin B Lipid Complex Injection)
`EVACET® (Liposomal Doxorubicin Injection)
`1998
`
`MARKETING AUTHORISATION APPLICATIONS
`
`2000 MYOCET® (Liposomal Doxorubicin Injection)
`
`
`ORIGINAL ARTICLES
`
`1. Cagen, A., Janoff, A.S., Bus, J.S. and Gibson, J.E.: Effects of paraquat (methylviologen) on liver function in
`mice. J. Pharm. Exper. Ther. 198, 222-229, 1976.
`
`
`2. Janoff, A.S. and Rosenberg, B.: Chemically evoked hypothermia in the mouse: Towards a method for
`investigating thermodynamic parameters of aging and death in mammals. Mech. Aging and Develop. 7, 335-
`349, 1978.
`
`
`3. Janoff, A.S., Haug, A. and McGroarty, E.J.: Relationship of growth temperature and thermotropic lipid
`phase changes in cytoplasmic and outer membranes from E. coli. Biochem. Biophys. Acta 555, 56-66, 1979.
`
`
`4. Janoff, A.S., Coughlin, R.T., Racine, F.M., McGroarty, E.J. and Vary, J.C.: Use of electron spin resonance
`to study Bacillus megaterium spore membranes. Biochem. Biophys. Res. Comm. 89, 565-570, 1979.
`
`
`5. Janoff, A.S., Gupte, S. and McGroarty, E.J.: Correlation between temperature range of growth and structural
`transitions in membranes and lipids of E. coli K12. Biochim. Biophys. Acta 598, 641-644, 1980.
`
`
`6. Janoff, A.S., Haug, A. and McGroarty, E.J.: Anesthetics alter outer membrane architecture and temperature
`range of growth of Escherichia coli K12. Biochem. Biophys. Res. Comm. 95, 1364-1371, 1980.
`
`
`7. Janoff, A.S., Mazarow, D.L., Coughlin, R.T., Bowdler, A.J., Haug, A. and McGroarty, E.J.: The
`modification of human erythrocyte membrane structure by membrane stabilizers: An electron spin resonance
`study. Am. J. Hematol. 10, 171-179, 1981.
`
`
`8. Janoff, A.S., Pringle, M.J. and Miller, K.W.: Correlation of general anesthetic potency with solubility in
`membranes. Biochim. Biophys. Acta 649, 125-128, 1981.
`
`
`9. Renshaw, P., Janoff, A.S. and Miller, K.W.: On the nature of dilute aqueous cholesterol suspensions. J. Lipid
`Research 24, 47-51, 1983.
`
`
`10. Janoff, A.S., Carpenter-Green, S., Weiner, A.L., Seibold, J., Weissmann, G. and Ostro, M.J.: Novel
`liposome composition for a rapid colorimetric test for systemic lupus erythematosus. Clin. Chem. 29, 1587-
`1592, 1983.
`
`11. Madden, T.D., Bally, M.B., Hope, M.J., Cullis, P.R., Schieren, H.P. and Janoff, A.S.: Protection of large
`unilamellar vesicles by trehalose during dehydration: Retention of vesicle contents. Biochim. Biophys. Acta
`817, 67-74, 1985.
`
`
`12. Mayer, L.D., Hope, M.J., Cullis, P.R. and Janoff, A.S.: Solute distributions and trapping efficiencies
`observed in freeze-thawed multilamellar vesicles. Biochim. Biophys. Acta 817, 193-196, 1985.
`
`13. Gruner, S.M., Lenk, R.P., Janoff, A.S. and Ostro, M.J.: Novel multi- Lamellar lipid vesicles: comparison of
`physical characteristics of multilamellar liposomes (MLVs) and stable pleurilamellar vesicles (SPLVs).
`Biochemistry 24, 2833-2842, 1985.
`
`
`
`
`
`
`
`
`
`Moderna Ex 1018-p. 5
`Moderna v Arbutus
`
`

`

`
`
`
`
`
`
`14. Richards, W.L., Habbersett, R.C., Scher, I., Janoff, A.S., Schieren, H.P., Mayer, L.D., Cullis, P.R. and
`Alving, C.R.: Influence of vesicle size on complement-dependent immune damage to liposomes. Biochim.
`Biophys. Acta 855, 223-230, 1986.
`
`
`15. Rauch, J., Tannenbaum, M., Cullis, P.R., Tilcock, C.P.S., Hope, M.J. and Janoff, A.S.: Human hybridoma
`lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J. Biol. Chem. 261,
`9672-9677, 1986.
`
`
`16. Firestone, L., Janoff, A.S. and Miller, K.W.: Lipid dependent differential effects of stereoisomers of
`anesthetic alcohols. Biochim. Biophys. Acta 898, 90-96, 1987.
`
`
`17. Janoff, A.S., Boni, L.T., Popescu, M.C., Minchey, S.R., Cullis, P.R., Madden, T.D., Taraschi, T., Gruner,
`S.M., Shyamsunder, E., Tate, M.W., Mendelsohn, R. and Bonner, D.: Unusual lipid structures selectively
`reduce the toxicity of Amphotericin B. Proc. Nat'l. Acad. Sci. USA 85, 6122-6126, 1988.
`
`18. Janoff, A.S., Kurtz, C.L., Jablonski, R.L., Minchey, S.R., Boni, L.T., Gruner, S.M., Cullis, P.R., Mayer,
`L.D. and Hope, M.J.: Characterization of cholesterol hemisuccinate and alpha tocopherol hemisuccinate
`vesicles. Biochim. Biophys. Acta 941, 165-175, 1988.
`
`
`19. Perkins, W.R., Minchey, S.R., Ostro, M.J. and Janoff, A.S.: The captured volume of multilamellar vesicles.
`Biochim. Biophys. Acta 943, 103-107, 1988.
`
`
`20. Madden, T.D., Janoff, A.S. and Cullis, P.R.: Incorporation of Amphotericin B into large unilamellar vesicles
`composed of phosphatidylcholine and phosphatidylglycerol. Chem. Phys. Lipids 52, 189-198, 1989.
`
`
`21. Rauch, J., Tannenbaum, M. and Janoff, A.S.: Distinguishing plasma lupus anticoagulants from antifactor
`antibodies using hexagonal (II) phase phospholipids. Thrombosis and Hemostasis 62, 892-896, 1989.
`
`
`22. Rauch, J. and Janoff, A.S: Phospholipid in the hexagonal (II) phase is immunogenic: Evidence for
`immunorecognition of nonbilayer lipid phases in in vivo. Proc. Nat'l. Acad. Sci. USA 87, 4112-4114, 1990.
`
`
`23. Boni, L.T., Perkins, W., Minchey, S.R., Bolcsak, L.E., Gruner, S.M., Cullis, P.R., Hope, M.J. and Janoff,
`A.S.: Polymorphic phase behavior of alpha tocopherol hemisuccinate. Chem. Phys. Lipids 54, 193-203, 1990.
`
`
`24. Perkins, W.R., Minchey, S.R., Boni, L.T., Swenson, C.E., Popescu, M.E., Pasternack, R.F. and Janoff,
`A.S.: Amphotericin B phospholipid interactions responsible for reduced mammalian cell toxicity. Biochim.
`Biophys. Acta 1107, 271-282, 1992.
`
`25. Janoff, A.S., Minchey, S.R., Perkins, W.R., Boni, L.T., Seltzer, S.E., Adams, D.F. and Blau, M.:
`Interdigitation-fusion vesicles. A new approach for selective opacification of the RES. Inves. Radiol. 26, S167-
`S168, 1992.
`
`
`26. Seltzer, S.E., Janoff, A.S., Blau, M., Adams, D., Minchey, S.R. and Boni, L.T.: Biodistribution and imaging
`characteristics of iotrolan-carrying interdigitation-fusion vesicles. Inves. Radiol. 26, S169-S171, 1992.
`
`
`27. Boni, L.T., Minchey, S.R., Perkins, W.R., Ahl, P.L., Slater, J.L., Tate, M.W., Gruner, S.M. and Janoff,
`A.S.: Curvature dependent induction of the interdigitated gel phase in DPPC vesicles. Biochim. Biophys. Acta
`1146, 247-257, 1993.
`
`
`28. Ahl, P.L., Chen, L., Perkins, W.R., Minchey, S.R., Boni, L.T., Taraschi, T.F., Janoff, A.S.: Interdigitation-
`Fusion: A New Method for Producing Lipid Vesicles of High Internal Volume. Biochim. Biophys. Acta 1195,
`237-244, 1994.
`
`
`29. Eierman, D.F., Yagami, M., Erme, S.M., Minchey, S., Harmon, P.A., Pratt, K.J., Janoff, A.S.:
`Endogenously opsonized particles divert prostanoid action from lethal to protective in models of experimental
`endotoxemia. Proc. Nat’l. Acad. Sci. USA 92, 2815-2819, 1995.
`
`
`
`Moderna Ex 1018-p. 6
`Moderna v Arbutus
`
`

`

`
`
`
`
`
`
`
`
`
`
`
`
`30. Seltzer, S.E., Blau, M., Herman, L.W., Hooshmand, R.L., Herman, L.A., Adams, D.F., Minchey, S.R.,
`and Janoff, A.S.: Contrast Material-Carrying Liposomes: Biodistribution, Clearance, and Imaging
`Characteristics. Radiology 194, 775-781, 1995.
`
`
`31. Swenson, C.E., Bolcsak, L.E., Perkins, W.R., Janoff, A.S.: Lipid-based formulations of amphotericin B. J.
`Antimicrob. Chemother. 35, 707-713, 1995.
`
`
`32. Smalling, R.W., Feld, S., Ramanna, N., Amirian, J., Felli, P., Vaughn, W.K., Swenson, C., Janoff, A.S.:
`Infarct Salvage with Liposomal Prostaglandin E1 Administered by Intravenous Bolus Immediately Prior to
`Reperfusion in a Canine Infarction-Reperfusion Model. Circulation 92(4) 935-943, 1995.
`
`
`33. Ahmad, I., Perkins, W.R., Lupan, D.M., Selsted, M.E., Janoff, A.S.: Liposomal Entrapment of the
`Neutrophil-Derived Peptide Indolicidin Endows It with In Vivo Antifungal Activity. Biochim. Biophys. Acta;
`1237 109-114, 1995.
`
`34. Perkins, W.R., Dause, R.B., Li, X., David, T.S., Ahl, P.L., Minchey, S.R., Taraschi, T.F., Erramilli, S.,
`Gruner, S.M., Janoff, A.S.: Pressure Induced Fusion (PIF) Liposomes: A Solventless Sterilizing Method for
`Producing Large Phospholipid Vesicles. Journal of Liposome Research 5(3) 605-626, 1995.
`
`35. Perkins, W.R., Dause, R.B., Parente, R.A., Minchey, S.R., Neuman, K.C., Gruner, S.M., Taraschi, T.F.,
`and Janoff, A.S.: Role of Lipid Polymorphism in Pulmonary Surfactant. Science 273 330-332, 1996.
`
`36. Rauch, J. and Janoff, A.S.: Antibodies against phospholipids other than cardiolipin: potential roles for both
`phospholipid and protein. Lupus, 5, 498-502, 1996.
`
`37. Bhamra, R., Sa’ad A., Bolcsak, L.E., Janoff, A.S., Swenson, C.E.: Behavior of Amphotericin B Lipid
`Complex (ABELCETTM) in Plasma In Vitro and in the Circulation of Rats. Antimicrobial Agents and
`Chemotherapy, 41(5) 886-892, 1997.
`
`
`38. Sharma, A., Bernacki, R.J., Bolcsak, L., Cavanaugh, C., Harmon, P., Janoff, A.S., Mayhew, E.: Activity
`of Paclitaxel Liposome Formulations Against Human Ovarian Tumor Xenografts. International Journal of
`Cancer, 71, 103-107, 1997.
`
`39. Davidson, S.M.K., Cabral-Lilly, D., Maurio, F.P., Franklin, J.C., Minchey, S.R., Ahl, P.L., Janoff, A.S.:
`Association and Release of Prostaglandin E1 from Liposomes. Biochim. Biophys. Acta 1327, 97-106, 1997.
`
`40. Perkins, W., Dause, R.B., Li, X., Franklin, J.C., Cabral-Lilly, D.J., Zha, Y., Dank, E., Mayhew, E.G.,
`Janoff, A.S.: Combination of Antitumor Ether Lipid with Lipids of Complementary Molecular Shape Reduces
`Its Hemolytic Activity. Biochim. Biophys. Acta 1327, 61-68, 1997.
`
`
`41. Perkins, W., Li, X., Slater, J.L., Harmon, P.A., Ahl, P.L., Minchey, S.R., Janoff, A.S.: Solute Induced Shift
`of Phase Transition Temperature for Di-saturated PC Liposomes: Adoption of Ripple Phase Creates Osmotic
`Stress. Biochim. Biophys. Acta 1327, 41-51, 1997.
`
`42. Perkins, W.R., Vaughan, D.E., Plavin, S.R., Daley, W.L., Rauch, J., Lee, L., Janoff, A.S.: Streptokinase
`Entrapment in Interdigitation - Fusion Liposomes Improves Thrombolysis in an Experimental Rabbit Model.
`Thrombosis and Hemostasis 776, 1174-1178, 1997.
`
`
`43. Harmon, P., Cabral-Lilly, D., Reed, R.A., Maurio, F.P., Franklin, J.C., Janoff, A.: The Release and
`Detection of Endotoxin from Liposomes. Analytical Biochem 250, 139-146, 1997.
`
`
`44. Ahmad, I., Filep, J.J., Franklin, J.C., Janoff, A.S., Masters, G.R.., Pattassery, J., Peters, A., Schupsky,
`J.J., Zha, Y., Mayhew, E.: Enhanced Therapeutic Effects of Liposome-Associated 1--Octadecyl-2--
`methyl-sn-glycero-3-phosphocholine. Cancer Research 57, 1915-1921, 1997.
`
`
`45. Mayhew, E., Ahmad, I., Bhatia, S., Dause, R., Filep, J., Janoff, A.S., Kaisheva, E., Perkins, W., Zha, Y.,
`Franklin, J.C.: Stability of Association of 1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphocholine with
`Liposomes is Composition Dependent. Biochim. Biophys. Acta 1329, 139-148, 1997.
`
`Moderna Ex 1018-p. 7
`Moderna v Arbutus
`
`

`

`
`
`
`46. Peters, A.C., Ahmad, I., Janoff, A.S., Pushkareva, Marina Y., and E. Mayhew.: Growth Inhibitory Effects
`of Liposome-Associated 1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Lipids, 32, 1045-1054,
`1997.
`
`
`47. Ahl, P.L., Bhatia, S.K., Meers, P., Roberts, P., Stevens, R., Dause, R., Perkins, W.R., Janoff, A.S.:
`Enhancement of the In Vivo Circulation-Lifetime of DSPC Liposomes: Importance of Liposomal Aggregation
`versus Complement Opsonization. Biochim. Biophys. Acta, 1329, 370-382, 1997.
`
`
`48. Shangguan, T., Pak, C.C., Ali, S., Janoff, A.S., and Meers, P.: Cation-Dependent Fusogenicity of an N-acyl
`Phosphatidylethanolamine. Biochim. Biophys. Acta, 1368, 171-183, 1998.
`
`
`49. Swenson, C., Perkins, W., Roberts, P., Ahmad, I., Stevens, R., Stevens, D., and Janoff, A.: In vitro and In
`vivo Antifungal Activity of Amphotericin B Lipid Complex: Are Phospholipases Important? Antimicrobial
`Agents and Chemotherapy 42 767-771, 1998.
`
`
`50. Pak, C.C., Ali, S., Janoff, A.S., and Meers, P.: Triggerable Liposomal Fusion by Enzyme Cleavage of a
`Novel Peptide-Lipid Conjugate. Biochim.Biophys. Acta, 1372, 13-27, 1998.
`
`
`51. Li, X., Hirsh, D.F., Cabral-Lilly, D., Zirkel, A., Gruner, S.M. Janoff, A.S. and Perkins, W.R.: Doxorubicin
`Physical State in Solution and Inside Liposomes loaded via a pH Gradient. Biochim. Biophys. Acta, 1415, 23-
`40, 1998.
`
`
`52. Pak C.C., Erukulla R.K., Ahl, P.L., Janoff, A.S. and Meers, P.: Elastase-Activated Liposomal Delivery to
`Nucleated Cells. Biochim. Biophy. Acta 1419, 111-126, 1999.
`
`
`53. Spiegel, S., Olah, Z., Culvillier, O., Edsall, L., Janoff, A.: Differential Effects of Free and Liposome-
`Associated ET-18-OCH3 on Protein Kinase C. FEBS Letters 454, 137-141, 1999.
`
`54. Cuvillier, O., Mayhew, E., Janoff, A., Spiegel, S.: Liposomal ET-18-OCH3 Induces Cytochrome c-Mediated
`Apoptosis Independently of CD95 (APO-1/Fas) Signaling. Blood 94, 3583-3592, 1999.
`
`
`55. Ahmad, I., Masters, G.R., Schupsky, J.J. Nguyen, J., Ali, S., Janoff, A.S. and Mayhew, E.: Growth
`Inhibition of a Human Ovarian Tumor by a Novel Paclitaxel Derivative in SCID Mice. Oncology Res., 11,
`273-280, 1999.
`
`
`56. Pushkareva, M.Y., Janoff, A.S. and Mayhew, E.: Inhibition of Cell Division but not Nuclear division by 1-
`O-octadecyl-2-O-methy-sn-glycero-3-phosphocholine. Cell Biology International, 23, 817-828, 1999.
`
`
`57. Pushkareva, M.Y., Wannberg, S.L., Janoff, A.S., and Mayhew, E.: Increased Cell Surface Receptor
`Expression on U-937 cells Induced by 1-O-Octadecyl-2-O-methyl-sn-glycero-3-phosphocholine. Cancer
`Immunol. Immunother., 48, 569-578, 2000.
`
`
`58. Ali, S. Michey, S., Janoff, A.S. and Mayhew, E.: A Different Scanning Calorimetry Study of
`Phosphocholines Mixed with Paclitaxel and Its Bromoacylated Taxanes. Biophysical Journal, 78, 246-256,
`2000.
`
`
`59. X. Li, Cabral-Lilly, D., Janoff, A. S. and Perkins, W.R.: Complexation of Internalized Doxorubicin into
`Fiber Bundles Affects its Release Rate from Liposomes. Journal of Liposome Research, 10, 15-27, 2000.
`
`
`60. Perkins, W. R, Ahmad, I., Li, X., Hirsch, D.J.,, Masters, G.R., Fecko, C.J., Lee, J., Ali, S., Nguyen, J.,
`Schupsky, J., Herbert, C., Janoff, A.S., Mayhew, E.: Novel Therapeutic nano-particles (lipocores):
`Trapping poorly water soluble compounds. International Journal of Pharmaceutical Science, 200, 27-39, 2000.
`
`
`61. Rauch, J., Taraschi, F., Tannenbaum, M., Janoff, A.S. : Direct Binding of Lupus Anticoagulant Antibodies
`to Nonbilayer Phosphatidylethanolamine; Journal of Liposome Research 10 (1), 29-41, 2000.
`
`
`
`Moderna Ex 1018-p. 8
`Moderna v Arbutus
`
`

`

`62. Shangguan, T., Cabral-Lilly, D., Purandare, U., Godin, N., Ahl, P., Janoff, A. S. and Meers, P. A Novel
`N-Acyl Phosphatidylethanolamine-Containing Delivery System for Spermine-Condensed Plasmid DNA. Gene
`Therapy 7(9), 769-783, 2000.
`
`
`63. Meers, P., Ali, S., Erukulla, R. and Janoff, A. S. Inner Monolayer Fusion Assays Reveal Differential
`Monolayer Mixing Associated with Cation-Dependent Membrane Fusion. Biochim. Biophys. Acta 1467, 227-
`243, 2000.
`
`
`64. Subang, R., Levine, J.S., Janoff, A.S.,Davidson, S.M.K., Taraschi, T.F., Koike, T., Minvhey, S.R.,
`Whiteside, M, Tannebaum and Rauch, J.: Phospholipid-Bound 2 -Glycoprotein Antibodies. Journal of
`Autioimmunity 15, 21-32, 2000.
`
`
`65. Adedoyin, A., Swenson, C., Bolcsak, L. E., Hellman, A., Radowska, D., Horwith, G., Janoff, A. S.,
`Branch, R.A.: A Pharmacokinetic Study of Amphotericin B Lipid Complex Injection (Abelcet) in Patients
`with Definite or Probable Systemic Fungal Infections; Antimicrobial Agents and Chemotherapy, 44, 2900-2902,
`2000.
`
`
`66. Ali, S., Ahmad, I., Peters, A., Masters, G., Minchey, S., Janoff, A. S., Mayhew, E.: Hydrolyzable
`Hydrophobic Taxanes: Synthesis and Anti-Cancer Activities. Anti-Cancer Drug 12(2):117-28, 2001.
`
`
`67. Allen, C, Dos Santos, N, Gallagher R, Chiu GNC, Shu Y, Li WM, Johnstone SA, Janoff AS, Mayer LD,
`Webb MS and Bally MB “Controlling the Physical Behavior and Biological Performance of Liposome
`Formulations through Use of Surface Grafted Poly(ethylene glycol)” BioScience Reports 22(2):225-250, 2002
`
`
`68. Batist, G, Chi, K, Miller, W, Chia, S., Hasanbasic, F, Fisic, A, Mayer, LD, Swenson, C, Janoff, A,
`Gelmon, K, (2006) “Phase 1 study of CPX-1, a fixed ratio formulation of irinotecan ® and floxuridine (FLOX),
`in patients with advanced solid tumours.” Journal of Clinical Oncology 24, 82s, 2006
`
`
`69 Mayer LD, Harasym TO, Tardi PG, Harasym, NL, Shew CR, Johnstone SA, Ramsay EC, Bally MB,
`Janoff AS (2006) “Ratiometric dosing of anticancer drug combinations: controlling drug ratios after systemic
`administration regulates therapeutic activity in tumor-bearing mice” Mol Cancer Ther. 5(7):1854-63
`
`
`70. Janoff, A. Louie, A. Swenson, C., Cabral-Lilly, D. Batist, G. Harasym, T. Tardi,P. Chiarella, M. Mayer,
`L. (2006) Ratiometric dosing of anticancer drug combinations. 18th EORTC-NCI-AACR International
`Conference on Molecular Targets and Cancer Therapeutics, Prague, 7-10 Nov, 2006.
`
`71. Batist, G, Louie A, Chi K, Chia S, Gelmon K, Jewish General Hospital, McGill University, Montreal, PQ,
`Canada, Celator Pharmaceuticals Inc., Princeton, NJ, Miller, W., Swenson C. Janoff A, Mayer LD
`(2007) “Ratiometric dosing of irinotecan (IRI) and floxuridine (FLOX) in a phase 1 trial: A new approach for
`enhancing the activity of combination chemotherapy.” J. Proc. American Society of Clinical Oncology 25: 109s
`
`
`72 . Feldman, EJ, Lancet, JE., Kolitz, JE., Asatiani, E, Curcio, TJ., Burton, MK., Fricano, M, Begley, AR,
`Swenson, C, Mayer, LD, Janoff, AS, Louie, AC (2007) “Phase 1 Study of a Liposomal Carrier (CPX-351)
`Containing an Optimized, Synergistic, Fixed Molar Ratio of Cytarabine (Ara-C) and Daunorubicin (DNR) in
`Advanced Leukemias and Myelodysplastic Syndromes (MDS)” Blood (ASH Annual Meeting Abstracts) 2007
`110: Abstract 900, American Society of Hematology
`
`
`73. Feldman, E. Lancet, J, Kolitz, JE, Asianti, E., Swenson, C. Mayer, L., Janoff, A., Louie, A. (2008)
`Preclinical and Phase I Clinical Activity of CPX 351, a Liposomal carrier containing a fixed synergistic molar
`ratio of cytarabine and daunorubicin in advanced leukemias and myelodysplastic syndromes. 12th Annual
`International Congress on Hematological Malignancies.
`
`
`74. Batist, G. Gelmon,K.A., Chi,K.N., Miller,W.H., Chia,S.K.L., Mayer, L.D., Swenson< C.E., Janoff, A.S.
`and Louie, A.C. Saftey, Pharmokinetics, and Efficacy of CPX-1 Liposomal Injection in Patients with
`Advanced Solid Tumors. Clin.Cancer Res. 15, 692-700, 2009.
`
`
`
`
`
`Moderna Ex 1018-p. 9
`Moderna v Arbutus
`
`

`

`
`
`
`REVIEWS
`
`1. Janoff, A.S. and Miller, K.W.: A critical assessment of the lipid theories of general anesthetic action.
`"Biological Membranes" (D. Chapman, ed.), vol. 4, Academic Press, London, 1982.
`
`
`2. Janoff, A.S. and Rauch J.: The structural specificity of anti-phospholipid antibodies in autoimmune disease.
`Chem. Phys. Lipids 40, 315-332, 1986.
`
`
`3. Rauch, J., Tannenbaum, M., Tannenbaum, H., Ramelson, H., Cullis, P.R., Tilcock, C.P.S., Hope, M.J.
`and Janoff, A.S.: Hybridoma lupus anticoagulants distinguish between bilayer and nonbilayer phase lipid
`systems. Ann. New York Academy of Sciences, 475, 366-369, 1986.
`
`
`4. Hope, M.J., Bally, M.B., Mayer, L.D., Janoff, A.S. and Cullis, P.R.: Generation of multilamellar and
`unilamellar phospholipid vesicles. Chem. Phys. Lipids 40, 89-107, 1986.
`
`
`5. Cullis, P.R., Hope, M.J., Bally, M.B., Madden, T.D., Mayer, L.D. and Janoff, A.S.: Liposomes as
`pharmaceuticals. "Liposomes, Vol. II", (M. Ostro, ed.) Marcel Dekker, New York, 1987.
`
`6. Rauch, J., Tannenbaum, H., Senecal, J.-L., Janoff, A.S., Cullis, P.R. and Frojmovic, M.M.:
`Polyfunctional properties of hybridoma lupus anticoagulant antibodies. J. Rheumatol. 1403, 132-137, 1987.
`
`7. Janoff, A.S., Boni, L.T. and Rauch, J.: Phase defined lipid domains in biological membranes: A perspective.
`“Advances in membrane fluidity, Vol. 2", (R. Aloia, ed.), Alan R. Liss, Inc., New York, 1988.
`
`8. Janoff, A.S.: Liposomes and lipid structures as carriers of Amphotericin B. Eur. J. Clin. Micro. Infect. Dis.
`146-151, 1988.
`
`9. Rauch, J. and Janoff, A.S.: Role of monoclonal antibodies in understanding the interactions between anti-
`phospholipid antibodies and phospholipids, Phospholipid Binding Antibodies (E.N. Harris, T. Exner, G.R.V.
`Hughes and R. Asherson, Eds.), CRC, Inc., Boca Raton, 107-122, 1991.
`
`10. Janoff, A.S.: Lipids, liposomes and rational drug design. Lab Inves. 66, 655-658, 1992.
`
`11. Rauch, J. and Janoff, A.S.: The nature of antiphospholipid antibodies. J. Rheumatol. 19-11, 1782-1780, 1992.
`
`12. Perkins, W.P., Minchey, S.R., Ahl, P.L. and Janoff, A.S.: The determination of liposome captured volume.
`Chem. Phys. Lipids 64, 197-217, 1993.
`
`13. Janoff, A.S., Perkins, W.R., Saletan, S.L. and Swenson, C.E.: Amphotericin B lipid complex (ABLC™): A
`molecular rationale for the attenuation of Amphotericin B related toxicities. Journal of Liposome Research.
`Marcel Dekker, Inc., New York, 3(3), 451-471, 1993.
`
`
`14. Swenson, CE. and Janoff, A.S.: Preclinical Studies with Amphotericin B Lipid Complex. Drugs of Today, 32
`397-402, 1996.
`
`
`15. Swenson, C.E., Freitag, J. and Janoff, A.S.: Lipid-Based Pharmaceuticals in Clinical Development. “Medical
`Applications of Liposomes”, (D.D. Lasic and D. Papahadjopoulos, Eds.), Elsevier, Amsterdam, 1997.
`
`
`16. Harasym T, Tardi P, Johnstone S, Mayer LD, Bally MB and Janoff A (2007) “Fixed Drug Ratio Liposome
`Formulations of Combination Cancer Therapeutics” In Liposome Technology Third Edition Volume III
`Interactions of Liposomes with Biological Milieu. (G Gregoriadis, ed) pp. 25-46, Informa Healthcare USA, Inc. NY
`
`
`17. Mayer, L.D. and Janoff, A. S. Optimizing Combination Chemotherapy by Controlling Drug Ratios.
`Molecular Interventions 7:216-223, 2007
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`
`Moderna Ex 1018-p. 10
`Moderna v Arbutus
`
`

`

`18. Janoff, A.S. Private Development Companies:Transforming Academic Research into New Treatment Options for
`Cancer. Molecular Interventions 10:65-68, 2010
`
`
`
`UNITED STATES PATENTS
`
`
`
`1. Lenk, R.P., Fountain, M., Janoff, A.S., Ostro, M.J. and Popescu, M.: Stable plurilamellar vesicles, their
`preparation and use, U.S. Patent N